Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes.

Cancer treatment reviews - 1 Sept 2024

Calabrese A, von Arx C, Tafuti A A, Pensabene M, De Laurentiis M

Abstract excerpt

The detection of germline pathogenic variants (gPVs) in BRCA1/2 and other breast cancer (BC) genes is rising exponentially thanks to the advent of multi-gene panel testing. This promising technology, coupled with the availability of specific therapies for BC BRCA-related, has increased the number of patients eligible for genetic testing. Implementing multi-gene panel testing for hereditary BC screening holds...

Topics

Humans
Breast Neoplasms
Female
Genetic Testing
Genetic Predisposition to Disease
BRCA1 Protein
BRCA2 Protein

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 38870570
DOI: 10.1016/j.ctrv.2024.102785

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes.PMID 38870570Read ↗

Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2.Semantic proximity Read ↗

Cancer genetic counselling for hereditary breast cancer in the era of precision oncology.Semantic proximity Read ↗

Multi gene panel testing for hereditary breast cancer - is it ready to be used?Semantic proximity Read ↗

A study of over 35,000 women with breast cancer tested with a 25‐gene panel of hereditary cancer genesSemantic proximity Read ↗

BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testingSemantic proximity Read ↗

Gene Panel Testing in Hereditary Breast Cancer.Semantic proximity Read ↗

The relationship between mutation carriage of BRCA1/2 and clinicopathological characteristics in women with breast cancer - experience from a diagnostic centre in Turkey.Semantic proximity Read ↗

Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer.Semantic proximity Read ↗

Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline VariantsSemantic proximity Read ↗

Breast cancer multigene germline panel testing in mainstream oncology based on clinical-public health utility (cancer mortality benefit): ESMO Precision Oncology Working Group recommendationsSemantic proximity Read ↗

Germline Pathogenic Variants in HER2-Positive Breast Cancer: Spectrum and Clinical Implications in a High-Risk Chinese Cohort.Semantic proximity Read ↗

Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.